2022
DOI: 10.1093/ecco-jcc/jjab232.560
|View full text |Cite
|
Sign up to set email alerts
|

P433 Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc

Abstract: Background Ustekinumab is an effective drug in Crohn′s Disease (CD) and most frequently used dose is subcutaneous (sc), 90 mg /, 8 weeks. With the usual sc doses (90 mg every, 8–12 weeks) some patients will only partially respond or experience secondary loss of response. In this situation, shortening of the administration interval (e.g., every, 4 or, 6 weeks) or a reinduction dose has been proposed. Another unexplored option is intravenous (IV) administration at regular intervals when shorten… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Nevertheless, maintenance with the IV UST dose has been less studied. The longest work is by Garcia-Alvarado et al , 21 who have also looked at this; it is a poster published at European Crohn’s and Colitis Organisation (ECCO) in 2022. A total of 79 patients were included.…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, maintenance with the IV UST dose has been less studied. The longest work is by Garcia-Alvarado et al , 21 who have also looked at this; it is a poster published at European Crohn’s and Colitis Organisation (ECCO) in 2022. A total of 79 patients were included.…”
Section: Discussionmentioning
confidence: 99%